Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient

Pediatrics

Volumn 135, Issue 2, 2015, Pages e551-e555

  Chehade, Hassib ^a   Rotman, Samuel ^b   Matter, Maurice ^b   Girardin, Eric ^c   Aubert, Vincent ^b   Pascual, Manuel ^b  

^a Centre Hospitalier Universitaire Vaudois   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BASILIXIMAB; COMPLEMENT COMPONENT C4D; COMPLEMENT MEMBRANE ATTACK COMPLEX; CREATININE; ECULIZUMAB; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLIN G; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; ALLOANTIBODY; HLA ANTIGEN; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ANTIBODY BLOOD LEVEL; ANTIBODY MEDIATED REJECTION; ARTERITIS; ARTICLE; BASE MISPAIRING; CAPILLARITIS; CASE REPORT; CELLULAR REJECTION; CHILD; CREATININE BLOOD LEVEL; DESENSITIZATION; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; EARLY INTERVENTION; END STAGE RENAL DISEASE; FLOW CYTOMETRY; FLUORESCENCE; GLOMERULONEPHRITIS; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; KIDNEY TUBULE; KIDNEY TUBULE DISORDER; LYMPHOCYTOTOXICITY; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; NEPHRONOPHTHISIS; OLIGURIA; PEDIATRICS; PERITUBULAR CAPILLARY; PLASMAPHERESIS; POSTOPERATIVE PERIOD; PROTEINURIA; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE; ACUTE DISEASE; BLOOD; GRAFT REJECTION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; MULTIMODALITY CANCER THERAPY; PASSIVE IMMUNIZATION; REOPERATION;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; COMBINED MODALITY THERAPY; DESENSITIZATION, IMMUNOLOGIC; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNIZATION, PASSIVE; ISOANTIBODIES; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; PLASMAPHERESIS; REOPERATION; TRANSPLANTATION IMMUNOLOGY;

EID: 84922658935     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-2275     Document Type: Article

References (25)

1. Djamali A, Kaufman DB, Ellis TM, Zhong W, Matas A, Samaniego M. Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant. 2014;14(2):255-271
2. Moll S, Pascual M. Humoral rejection of organ allografts. Am J Transplant. 2005;5(11):2611-2618
3. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008;359(3):242-251
4. Halloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation. 1990;49(1):85-91
5. Al-Badr W, Kallogjeri D, Madaraty K, Oliver D, Bastani B, Grossman BJ. A retrospective review of the outcome of plasma exchange and aggressive medical therapy in antibody mediated rejection of renal allografts: a single center experience. J Clin Apher. 2008;23(6):178-182
6. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant. 2011;11(11):2405-2413
7. Trpkov K, Campbell P, Pazderka F, Cock field S, Solez K, Halloran PF. Pathologic features of acute renal allograft rejection associated with donor-specific antibody, analysis using the Banff grading schema. Transplantation. 1996;61(11):1586-1592
8. Collins AB, Schneeberger EE, Pascual MA, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol. 1999;10(10):2208-2214
9. Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int. 1993;43(6):1333-1338
10. Rotman S, Collins B, Colvin RB. C4d deposition in allografts: current concepts and interpretation. Transplant Rev. 2005;19(2):65-77
11. Aubert V, Venetz JP, Pantaleo G, Pascual M. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol. 2009;70(8):580-583
12. Hunt EA, Jain NG, Somers MJ. Apheresis therapy in children: an overview of key technical aspects and a review of experience in pediatric renal disease. J Clin Apher. 2013;28(1):36-47
13. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010;21(8):1398-1406
14. Burns JM, Cornell LD, Perry DK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant. 2008;8(12):2684-2694
15. Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant. 2009;9(1):231-235
16. Lonze BE, Dagher NN, Simpkins CE, et al. Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access. Am J Transplant. 2010;10(9):2154-2160
17. Biglarnia AR, Nilsson B, Nilsson T, et al. Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. Transpl Int. 2011;24(8):e61-e66
18. Stewart ZA, Collins TE, Schlueter AJ, et al. Case report: eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant. Transplant Proc. 2012;44(10):3033-3036
19. Ghirardo G, Benetti E, Poli F, et al. Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody. Pediatr Transplant. 2014;18(1):E1-E5. doi:10.1111/petr.12187
20. Noone D, Al-Matrafi J, Tinckam K, et al. Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. Am J Transplant. 2012;12(9):2546-2553
21. Al-Akash SI, Almond PS, Savell VH Jr, Gharaybeh SI, Hogue C. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol. 2011;26(4):613-619
22. Christmann M, Hansen M, Bergmann C, Schwabe D, Brand J, Schneider W. Eculizumab as first-line therapy for atypical hemolytic uremic syndrome. Pediatrics. 2014;133(6). Available at: www.pediatrics.org/cgi/content/full/133/6/e1759
23. Venetz JP, Pascual M. New treatments for acute humoral rejection of kidney allografts. Expert Opin Investig Drugs. 2007;16(5):625-633
24. Pascual M, Saidman S, Tolkoff-Rubin N, et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation. 1998;66(11):1460-1464
25. Dawson KL, Parulekar A, Seethamraju H. Treatment of hyperacute antibodymediated lung allograft rejection with eculizumab. J Heart Lung Transplant. 2012;31(12):1325-1326